STOCK TITAN

Precision Peptide Company (PNGAF) Stock News

PNGAF OTC

The Precision Peptide Company reports developments around advanced peptide formulations and delivery systems for the wellness market. Recurring updates include the Amino Innovations platform, needle-free transdermal peptide patches, the BPC-157 patch, the Immune Defense Patch formulated with Thymosin Alpha-1, and broader work on oral and transdermal delivery technology.

Company news also covers capital and governance actions such as warrant exercises, restricted share units, stock options, debt settlement, material agreements, and commentary on the evolving U.S. regulatory framework for peptide substances. The company describes products manufactured in an approved U.S. facility and distributed across North America.

Rhea-AI Summary

The Precision Peptide Company (PNGAF) received approval to operate its own U.S. TikTok Shop storefront, adding a direct sales channel. TikTok Shop had 53.2 million U.S. buyers in 2025. HAIR scalp and hair serum is the first product live. The company plans to add more products from its U.S.-made range, with each additional product subject to TikTok Shop review.

The approval follows TikTok's October 2026 decision to restrict searches for several peptide names. Each product the company brings to the shop is made in an approved U.S. facility and backed by a third-party certificate documenting test results. The storefront advances the company's stated 2027 distribution expansion priority and adds to its existing online store and nationwide retail distribution of its U.S.-made over-the-counter range.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
none
-
Rhea-AI Summary

The Precision Peptide Company (PNGAF) has introduced free shipping to all 50 U.S. states on its entire over-the-counter range, effective immediately.

The offer covers all seven products ordered through store.precisionpep.co, including five capsule products, a topical serum and a transdermal patch. The U.S.-made range is available without a prescription. Nationwide retail sales began on July 30, 2026. The company says removing shipping fees is intended to lower the cost of an initial purchase and encourage repeat orders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.45%
Tags
none
-
Rhea-AI Summary

The Precision Peptide Company (PNGAF) reviewed its U.S. platform rollout and outlined product launches and distribution expansion for 2027. Its platform serves all 50 states, with 16 prescription therapies and seven over-the-counter products. It secured exclusive manufacturing rights for four patch formulations; the Recovery Patch is on sale.

The company plans to launch its Thymosin Alpha-1 patch, with delivery of its 20,000-unit order expected in January 2027, and advance tirzepatide and GLP3 patches through U.S. testing. Financing included approximately C$1.3 million from warrant exercises and a $2,000,000 common-share offering at $0.50 per share.

An FDA advisory committee supported considering six peptides for the pharmacy-compounding list. An HHS draft policy describes a potential interim pathway; it is non-binding and is not FDA approval. The company is evaluating its application with its compounding partner.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.78%
Tags
none
Rhea-AI Summary

The Precision Peptide Company (PNGAF) is adding six peptides to its prescription platform, with patient availability expected in November 2026. The additions are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Work began within a week of the October 30 publication of an interim U.S. Department of Health and Human Services policy.

The policy provides conditional enforcement discretion for compounding these peptides while FDA develops its permitted bulk-substance list. It is non-binding and does not constitute FDA approval; final inclusion requires future rulemaking. The company plans single-ingredient products in specified dosage forms, prescribed after review by U.S.-licensed clinicians and compounded by licensed U.S. pharmacies. Patient availability remains subject to applicable law and pharmacy supply.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none
-
Rhea-AI Summary

The Precision Peptide Company (OTCQB: PNGAF) is evaluating a draft HHS peptide-compounding policy with its U.S. pharmacy partner.

Published October 30, 2026, the draft describes potential interim enforcement discretion for six peptides under section 503A, the U.S. patient-specific compounding pathway. It recognizes oral and topical routes for BPC-157 and KPV, intranasal Semax, and injectable routes for other listed peptides. The company has a U.S. 503A pharmacy agreement and previously announced a formulary of 16 prescription therapies across seven therapy areas.

The draft is non-binding, may be revised or withdrawn, and requires sourcing, prescription and safety-reporting conditions. It does not constitute FDA approval; additions to the permitted bulk-substance list depend on future FDA rulemaking. The company has not announced a formulary change under the draft.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.74%
Tags
none
-
Rhea-AI Summary

The Precision Peptide Company (PNGAF) has expanded its U.S. telehealth formulary to 16 prescription therapies, quadrupling the range since launch. The increase from four therapies came less than four months after nationwide telehealth access began. The formulary spans seven therapy areas, including weight management, recovery and sexual wellness.

The company also introduced stacked protocols, allowing clinicians to manage multiple therapies within one personalized plan. Prescriptions require clinical review by a U.S.-licensed clinician, with medications compounded domestically and shipped across all 50 states. These compounded medications are not FDA-approved; individual therapy availability depends on applicable law and pharmacy supply.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.25%
Tags
none
Rhea-AI Summary

The Precision Peptide Company (PNGAF) highlighted the scientific leadership and product development approach behind its existing peptide formulation platform.

Co-founder and Chief Scientific Officer Justin Kirkland has more than thirty years of peptide-making experience. The approach combines U.S. chemical synthesis, an additional purification step and independent testing. In May 2026, independent testing measured the BPC-157 Recovery Patch at 95.5% purity and 2.02 mg of BPC-157 per patch. The company received a 20,000-unit production run in July 2026, and the patch is commercially available. A research collaboration with the University of Alberta provides access to pharmaceutical testing expertise and facilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
-
Rhea-AI Summary

The Precision Peptide Company (PNGAF) secured exclusive manufacturing rights from its U.S. manufacturer for all four of its transdermal peptide patch formulations. The arrangement covers BPC-157, Thymosin Alpha-1 (TA1), tirzepatide and GLP3, each to be produced solely for the company.

The BPC-157 Recovery Patch is already on sale, with approximately 20,000 units received in July 2026. TA1 entered formal U.S. testing in September 2026; 20,000 units were ordered in October 2026, with delivery expected in January 2027. Tirzepatide and GLP3 remain in development, and the company intends to advance them through testing and commercial production. In 2026, the company switched to a direct-to-consumer and telehealth platform across all 50 U.S. states and opened wholesale distribution to clinics, medical spas, gyms and retailers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.45%
Tags
none
-
Rhea-AI Summary

The Precision Peptide Company (PNGAF) has begun U.S. development of GLP3, the fourth product in its needle-free peptide patch line.

The company plans to take GLP3 through U.S. formulation and formal testing, followed by a commercial production order and release. Its existing lineup includes the Recovery Patch (BPC-157), which is on sale, Thymosin Alpha-1 (TA1), which is in production, and tirzepatide, which is in development. An order for 20,000 TA1 patches has been placed, with delivery expected in January 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
Rhea-AI Summary

The Precision Peptide Company (PNGAF) has advanced its needle-free tirzepatide transdermal patch into formal testing in the United States. The patch, first announced as under development on August 19, 2026, is designed to deliver the peptide through the skin. Testing is conducted entirely through the company's domestic product-development infrastructure. Commercial production remains subject to testing results.

This is the third product to enter the company's staged patch-development pathway. The BPC-157 patch previously progressed through formulation, independent third-party testing and an initial 20,000-unit commercial production order; the TA-1 patch subsequently entered formal U.S. testing. The company plans to commercialize the tirzepatide patch through its existing direct-to-consumer and telehealth-supported infrastructure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.66%
Tags
none

FAQ

What is the current stock price of Precision Peptide (PNGAF)?

Precision Peptide (PNGAF) last closed at $0.1424.

What is the market cap of Precision Peptide (PNGAF)?

The market cap of Precision Peptide (PNGAF) is approximately $7.9M.